• Abdelgawad, N., Miranda, J. C., Wasserman, S., Lanni, F., Antilus-Sainte, R., Kaya, F., Zimmerman, M., Gengenbacher, M., Dartois, V., & Denti, P. (2024). Pharmacokinetic Modelling of Rifampicin, Isoniazid, Pyrazinamide, Linezolid, and Rifabutin in CNS Tissues: A Rabbit Model Study of Tuberculosis Meningitis. International Workshop on Clinical Pharmacology of Tuberculosis Drugs.

  • Abdelgawad, N., Wasserman, S., Abdelwahab, M. T., Davis, A., Stek, C., Wiesner, L., Black, J., Meintjes, G., Wilkinson, R. J., & Denti, P. (2024). Linezolid population pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis. The Journal of Infectious Diseases, 229(4), 1200–1208. https://doi.org/10.1093/infdis/jiad413

  • Atoyebi, S., Montanha, M. C., Nakijoba, R., Orrell, C., Mugerwa, H., Siccardi, M., Denti, P., & Waitt, C. (2024). Physiologically Based Pharmacokinetic Modelling of the Co-administration of Ritonavir-Boosted Atazanavir and Rifampicin in Children Co-treated for HIV and Tuberculosis.https://doi.org/10.21203/rs.3.rs-5068722/v1

  • Combrinck, J., Tshavhungwe, P., Rohlwink, U., Enslin, N., Thango, N., Lazarus, J., Kriegler, K., Castel, S., Abdelgawad, N., & Mcilleron, H. (2024). Rifampicin and protein concentrations in paired spinal versus ventricular cerebrospinal fluid samples of children with tuberculous meningitis. Journal of Antimicrobial Chemotherapy, 79(2), 280–286. https://doi.org/10.1093/jac/dkad371

  • Gausi, K., Ignatius, E. H., de Jager, V., Upton, C., Kim, S., McKhann, A., Moran, L., Wiesner, L., von Groote-Bidlingmaier, F., & Marzinek, P. (2024). High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 210(3), 343–351. https://doi.org/10.1164/rccm.202311-2004OC

  • Gausi, K., Mugerwa, H., Siccardi, M., Montanha, M. C., Lamorde, M., Wiesner, L., D’Avolio, A., McIlleron, H., Wilkins, E., & de Nicolò, A. (2024). Pharmacokinetics and safety of twice-daily ritonavir-boosted atazanavir with rifampicin. Clinical Infectious Diseases, 78(5), 1246–1255. https://doi.org/10.1093/cid/ciad700

  • Gebreyesus, M. S., Dresner, A., Wiesner, L., Coetzee, E., Verschuuren, T., Wasmann, R., & Denti, P. (2024). Dose optimization of cefazolin in South African children undergoing cardiac surgery with cardiopulmonary bypass. CPT: Pharmacometrics & Systems Pharmacology, 13(9), 1595–1605. https://doi.org/10.1002/psp4.13196

  • Holovchak, A., McIlleron, H., Denti, P., & Schomaker, M. (2024). Recoverability of causal effects under presence of missing data: a longitudinal case study. Biostatistics, kxae044. https://doi.org/10.1093/biostatistics/kxae044

  • Huang, Z., Denti, P., Mistry, H., & Kloprogge, F. (2024). Machine learning and artificial intelligence in PK‐PD modeling: fad, friend, or foe? Clinical Pharmacology and Therapeutics, 115(4), 652. https://doi.org/10.1002/cpt.3165

  • Idro, R., Nkosi-Gondwe, T., Opoka, R. O., Ssenkusu, J. M., Kalibbala, D. M., Tsirizani, L., Akun, P., Rujumba, J., Nambatya, W., & Kamya, C. (2024). Weekly Dihydroartemisinin-Piperaquine Versus Monthly Sulphadoxine-Pyrimethamine for Malaria  Chemoprevention in Children with Sickle Cell Anaemia in Uganda and Malawi: A Randomised, Double-Blind, Placebo-Controlled Trial (Chemcha). In Pre-print. https://dx.doi.org/10.2139/ssrn.4835839

  • Kengo, A., Nabeemeeah, F., Denti, P., Sabet, R., Okyere-Manu, G., Abraham, P., Weisner, L., Mosala, M. H., Tshabalala, S., & Scholefield, J. (2024). Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy, 68(5), e01583-23. https://doi.org/10.1128/aac.01583-23

  • Maitra, A., Wijk, M., Margaryan, H., Denti, P., McHugh, T. D., & Kloprogge, F. (2024). The impact of physiological state and environmental stress on bacterial load estimation methodologies for Mycobacterium tuberculosis. Scientific Reports, 14(1), 26108. https://doi.org/10.1038/s41598-024-74318-3

  • Mpofu, R., Kawuma, A. N., Wasmann, R. E., Akpomiemie, G., Chandiwana, N., Sokhela, S. M., Moorhouse, M., Venter, W. D. F., Denti, P., & Wiesner, L. (2024). Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa. British Journal of Clinical Pharmacology, 90(5), 1247–1257. https://doi.org/10.1111/bcp.16009

  • Namale, P. E., Boloko, L., Vermeulen, M., Haigh, K. A., Bagula, F., Maseko, A., Sossen, B., Lee-Jones, S., Msomi, Y., & McIlleron, H. (2024). Testing novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB): protocol for a randomised controlled trial. Trials, 25(1), 311. https://doi.org/10.1186/s13063-024-08119-4

  • Ndzamba, B., Denti, P., McIlleron, H., Smith, P., Mthiyane, T., Rustomjee, R., Onyebujoh, P., & Reséndiz-Galván, J. E. (2024). Pharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV. Antimicrobial Agents and Chemotherapy, e01200-24. https://doi.org/10.1128/aac.01200-24

  • Pillai, G., Mouksassi, S., Asiimwe, I. G., Rayner, C. R., Kern, S., Sinxadi, P., Denti, P., Decloedt, E., Waitt, C., & Ogutu, B. R. (2024). Advancing pharmacometrics in Africa—Transition from capacity development. CPT: Pharmacometrics & Systems Pharmacology https://doi.org/10.1002/psp4.13291

  • Schomaker, M., Denti, P., Bienczak, A., Burger, D., Díaz, I., Gibb, D. M., Walker, A. S., & McIlleron, H. (2024). Determining Targets for Antiretroviral Drug Concentrations: A Causal Framework Illustrated with Pediatric Efavirenz Data from the Chapas-3 Trial. Pharmacoepidemiology and Drug Safety, 33(12), e70051. https://doi.org/10.1002/pds.70051

  • Schomaker, M., McIlleron, H., Denti, P., & Díaz, I. (2024). Causal Inference for Continuous Multiple Time Point Interventions. Statistics in Medicine, 43(28), 5380–5400. https://doi.org/10.1002/sim.10246

  • Semere Gebreyesus, M., Wasmann, R. E., McIlleron, H., Oladokun, R., Okonkwo, P., Wiesner, L., Denti, P., & Rawizza, H. E. (2024). Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy. Antimicrobial Agents and Chemotherapy, 68(8), e00354-24. https://doi.org/10.1128/aac.00354-24

  • Tsirizani, L., Mohsenian Naghani, S., Waalewijn, H., Szubert, A., Mulenga, V., Chabala, C., Bwakura-Dangarembizi, M., Chitsamatanga, M., Rutebarika, D. A., & Musiime, V. (2024). Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV. Journal of Antimicrobial Chemotherapy, 79(11), 2990–2998. https://doi.org/10.1093/jac/dkae319

  • van Heerden, J. K., Meintjes, G., Barr, D., Zhao, Y., Griesel, R., Keene, C. M., Wiesner, L., Galileya, L. T., Denti, P., & Maartens, G. (2024). Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir–Lamivudine–Dolutegravir as First-Line or Second-Line Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes, 95(3), 260–267. https://doi.org/10.1097/qai.0000000000003341

  • Verma, R., da Silva, K. E., Rockwood, N., Wasmann, R. E., Yende, N., Song, T., Kim, E., Denti, P., Wilkinson, R. J., & Andrews, J. R. (2024). A nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing. American Journal of Respiratory and Critical Care Medicine, 209(12), 1486–1496. https://doi.org/10.1164/rccm.202309-1583OC

  • Waalewijn, H., Wasmann, R. E., Bamford, A., Gibb, D. M., McIlleron, H. M., Colbers, A., Burger, D. M., & Denti, P. (2024). Population pharmacokinetics of Dolutegravir in African Children: results from the CHAPAS-4 trial. Journal of the Pediatric Infectious Diseases Society, 13(9), 496–500. https://doi.org/10.1093/jpids/piae076

  • Wasserman, S., Antilus-Sainte, R., Abdelgawad, N., Odjourian, N. M., Cristaldo, M., Dougher, M., Kaya, F., Zimmerman, M., Denti, P., & Gengenbacher, M. (2024). Rifabutin central nervous system concentrations in a rabbit model of tuberculous meningitis. Antimicrobial Agents and Chemotherapy, 68(8), e00783-24. https://doi.org/10.1128/aac.00783-24

  • White, Y. N., Solans, B. P., Denti, P., van der Laan, L. E., Schaaf, H. S., Vonasek, B., Malik, A. A., Draper, H. R., Hussain, H., & Hesseling, A. C. (2024). Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis. Clinical Infectious Diseases, 78(3), 756–764. https://doi.org/10.1093/cid/ciae024

  • Wijk, M. Gausi, K., Malatesta, S., Weber, S. E., Court, R., Myers, B., Carney, T., Parry, C. D. H., Horsburgh, C. R., & White, L. F. (2024). The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs. Journal of Antimicrobial Chemotherapy, 79(8), 2022–2030. https://doi.org/10.1093/jac/dkae206